NEW YORK, Dec. 10-GlaxoSmithKline will use Beyond Genomics' systems biology platform to describe disease pathways and identify disease and drug response markers, the company said in a statement today.
The deal is an "evaluation agreement." Financial details and specifics of the agreement were not revealed.
Beyond Genomics, based in Waltham, Mass., combines proteomic and metabolomic analysis with pattern recognition and data mining software for a systems approach to drug discovery and development.
For further details, see the press release